Figure 1. The linear regression between the ECL immunoassay and the LC-MRM-MS assay results.

(A) For casirivimab, the correlation coefficient between the two methods is r² = 0.9568, p < 0.0001 and slope = 1.014. (B) For imdevimab, the correlation coefficient between the two methods is r² = 0.9562, p < 0.0001, and slope = 1.117. The 95% prediction intervals are shown with dotted lines.